1. ALLA AKTIER
  2. NYHETER
  3. DEVYSER DIAGNOSTICS

Devyser Diagnostics

Nyheter Devyser Diagnostics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to Devyser’s Q3 2026 results presentation

On Tuesday, November 3 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its interim report for the third quarter of 2026. The report will be published earlier the same day, at 07:30 a.m. CET.

The presentation will be held in English.

If you wish to participate via webcast, please use the link below.
https://portals.qbrick.com/devyser-diagnostics-q3-2026

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://event-registration.qbrick.com/AccBjhsSfoEnkWOx1pVdbctJg/01a11c3d-b3fc-71ac-b54f-1c950cd4d0a4/qbrick-meet-84cdadc9-8d98-4e7d-930a-779e0144d984

Speakers: CEO Jan Wahlström and CFO Niklas Axelsson

For more information, please contact:
Jan Wahlström, CEO 
Email: ir@devyser.com
Telephone: +46 8 562 158 50
 
Niklas Axelsson, CFO 
Email: ir@devyser.com 
Telephone: +46 8 562 158 50

About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.  

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.  

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.  

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.  

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.

Discover how we're shaping the future of lab diagnostics at www.devyser.com.  

Attachments
Invitation to Devyser’s Q3 2026 results presentation

Datum 2026-10-22, kl 10:00
Källa MFN
Bifogade filer
Invitation to Devyser’s Q3 2026 results presentation